United Therapeutics Corpo...
364.56
1.68 (0.46%)
At close: Jan 14, 2025, 3:59 PM
364.70
0.04%
After-hours Jan 14, 2025, 04:00 PM EST

United Therapeutics Corporation Revenue Breakdown

Quarter Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015Dec 31, 2014Sep 30, 2014Jun 30, 2014Mar 31, 2014Dec 31, 2013Sep 30, 2013Jun 30, 2013Mar 31, 2013Dec 31, 2012Sep 30, 2012Jun 30, 2012Mar 31, 2012Dec 31, 2011Jun 30, 2011
Adcirca Revenue 7.00M 5.70M 6.40M 6.80M 7.30M 7.50M 7.30M 10.40M 10.70M 10.40M 9.80M 8.10M 14.60M 23.60M 9.60M 21.60M 13.80M 19.40M 12.50M 27.80M 30.30M 29.10M 58.40M 41.70M 74.60M 109.80M 97.60M 93.10M 99.80M 120.60M 80.00M 112.70M 96.00M 90.90M 72.60M 91.58M 73.80M 68.08M 45.37M 73.55M 51.25M 55.32M 41.36M 52.05M 47.38M 43.73M 33.82M 38.18M 31.80M 30.22M 22.33M 22.65M 16.84M
Adcirca Revenue Growth +22.81% -10.94% -5.88% -6.85% -2.67% +2.74% -29.81% -2.80% +2.88% +6.12% +20.99% -44.52% -38.14% +145.83% -55.56% +56.52% -28.87% +55.20% -55.04% -8.25% +4.12% -50.17% +40.05% -44.10% -32.06% +12.50% +4.83% -6.71% -17.25% +50.75% -29.02% +17.40% +5.61% +25.21% -20.73% +24.10% +8.40% +50.06% -38.31% +43.51% -7.36% +33.74% -20.53% +9.86% +8.35% +29.29% -11.42% +20.05% +5.23% +35.35% -1.40% +34.46% n/a
Orenitram Revenue 113.20M 107.10M 106.20M 84.10M 92.00M 95.10M 88.20M 75.80M 87.50M 79.00M 82.80M 72.30M 85.20M 76.20M 72.40M 74.00M 74.70M 75.40M 69.00M 50.90M 62.00M 54.00M 24.90M 49.60M 53.80M 49.50M 52.20M 48.00M 52.50M 46.00M 39.30M 38.30M 40.70M 38.00M 40.20M 37.29M 34.39M 25.87M 20.89M 20.18M 14.46M 6.63M 136.11M 119.86M 132.32M 124.31M 114.68M 116.21M 120.81M 110.40M 110.55M 107.12M 104.89M
Orenitram Revenue Growth +5.70% +0.85% +26.28% -8.59% -3.26% +7.82% +16.36% -13.37% +10.76% -4.59% +14.52% -15.14% +11.81% +5.25% -2.16% -0.94% -0.93% +9.28% +35.56% -17.90% +14.81% +116.87% -49.80% -7.81% +8.69% -5.17% +8.75% -8.57% +14.13% +17.05% +2.61% -5.90% +7.11% -5.47% +7.81% +8.43% +32.93% +23.86% +3.52% +39.52% +118.03% -95.13% +13.55% -9.41% +6.44% +8.40% -1.32% -3.81% +9.43% -0.13% +3.20% +2.12% n/a
Product and Service, Other Revenue 5.50M 4.90M 6.20M 3.90M 1.90M 3.50M 2.50M 3.80M 114.00M 132.00M 131.70M 118.30M 125.40M 139.80M 130.20M 127.90M 124.50M 119.00M 145.30M 107.40M 168.30M 155.80M 155.50M 159.10M 153.60M 159.50M 126.80M 180.10M 187.30M 157.70M 145.80M 151.20M 152.40M 158.90M 139.80M 140.48M 150.07M 135.96M 146.28M 136.59M 142.88M 138.15M 107.09M 114.38M 120.31M 109.46M 94.64M 86.04M 88.30M 81.21M 70.07M 64.55M 61.81M
Product and Service, Other Revenue Growth +12.24% -20.97% +58.97% +105.26% -45.71% +40.00% -34.21% -96.67% -13.64% +0.23% +11.33% -5.66% -10.30% +7.37% +1.80% +2.73% +4.62% -18.10% +35.29% -36.19% +8.02% +0.19% -2.26% +3.58% -3.70% +25.79% -29.59% -3.84% +18.77% +8.16% -3.57% -0.79% -4.09% +13.66% -0.49% -6.39% +10.38% -7.06% +7.09% -4.40% +3.42% +29.01% -6.38% -4.92% +9.91% +15.65% +10.01% -2.57% +8.73% +15.90% +8.55% +4.43% n/a
Remodulin Revenue 128.30M 147.30M 128.00M 115.10M 131.10M 127.20M 121.40M 122.50M 257.70M 201.00M 172.00M 166.50M 164.20M 153.80M 123.00M 29.70M 129.50M 119.20M 102.90M 33.60M 110.80M 109.60M 103.80M 24.10M 107.80M 105.90M 94.60M 24.90M 88.90M 104.20M 87.40M 93.60M 101.80M 107.00M 102.20M 119.13M 121.72M 115.84M 113.38M 115.07M 119.69M 121.23M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Remodulin Revenue Growth -12.90% +15.08% +11.21% -12.20% +3.07% +4.78% -0.90% -52.46% +28.21% +16.86% +3.30% +1.40% +6.76% +25.04% +314.14% -77.07% +8.64% +15.84% +206.25% -69.68% +1.09% +5.59% +330.71% -77.64% +1.79% +11.95% +279.92% -71.99% -14.68% +19.22% -6.62% -8.06% -4.86% +4.70% -14.21% -2.13% +5.07% +2.17% -1.47% -3.86% -1.27% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Tyvaso Revenue 433.80M 398.20M 372.50M 676.40M 51.30M 318.90M 238.40M 242.30M 46.10M 44.50M 55.60M 50.00M 55.30M 53.10M 43.90M n/a 37.60M 29.00M 26.60M n/a 30.10M 25.10M 20.00M n/a 22.90M 19.80M 18.00M n/a 17.00M 16.10M 18.00M 13.20M 17.30M 17.80M 14.20M 15.71M 4.73M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Tyvaso Revenue Growth +8.94% +6.90% -44.93% +1218.52% -83.91% +33.77% -1.61% +425.60% +3.60% -19.96% +11.20% -9.58% +4.14% +20.96% n/a n/a +29.66% +9.02% n/a n/a +19.92% +25.50% n/a n/a +15.66% +10.00% n/a n/a +5.59% -10.56% +36.36% -23.70% -2.81% +25.35% -9.63% +232.29% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Unituxin Revenue 61.10M 51.70M 58.40M 54.20M n/a 44.30M 49.10M 36.70M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Unituxin Revenue Growth +18.18% -11.47% +7.75% n/a n/a -9.78% +33.79% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Revenue by Geography

Quarter Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2013Dec 31, 2012Dec 31, 2011
Non-Us Revenue 125.30M 122.20M 121.30M 1.41B 1.03B 846.61M 676.97M
Non-Us Revenue Growth +2.54% +0.74% -91.41% +36.77% +21.95% +25.06% n/a
United States Revenue 2.20B 1.81B 1.56B n/a n/a n/a n/a
United States Revenue Growth +21.39% +15.98% n/a n/a n/a n/a n/a

Operating Expense Breakdown

Quarter Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015
Selling, General, and Administrative Revenue 219.20M 177.60M 144.40M 132.20M 127.60M 130.00M 87.30M 166.10M 98.40M 141.50M 79.00M 127.90M 109.10M 112.80M 117.20M 158.70M 66.30M 105.90M 93.00M 105.20M 99.40M 39.60M 92.00M 79.20M 110.10M 83.10M -6.60M 159.10M 47.20M 67.40M 56.40M 139.50M 100.10M 72.20M 5.00M 148.56M -17.28M 109.99M 211.34M
Selling, General, and Administrative Revenue Growth +23.42% +22.99% +9.23% +3.61% -1.85% +48.91% -47.44% +68.80% -30.46% +79.11% -38.23% +17.23% -3.28% -3.75% -26.15% +139.37% -37.39% +13.87% -11.60% +5.84% +151.01% -56.96% +16.16% -28.07% +32.49% -1359.09% -104.15% +237.08% -29.97% +19.50% -59.57% +39.36% +38.64% +1344.00% -96.63% -959.93% -115.71% -47.96% n/a
Research and Development Revenue 103.50M 139.60M 104.10M 151.40M 84.70M 89.00M 82.90M 93.90M 66.10M 93.90M 69.00M 82.90M 79.20M 74.30M 303.70M 126.10M 68.70M 89.70M 73.20M 113.60M 85.70M 85.90M 897.40M 138.80M 101.10M 82.30M 35.70M 113.60M 55.00M 59.80M 36.20M 66.90M 45.90M 35.20M -400.00K 75.95M 9.53M 49.41M 110.21M
Research and Development Revenue Growth -25.86% +34.10% -31.24% +78.75% -4.83% +7.36% -11.71% +42.06% -29.61% +36.09% -16.77% +4.67% +6.59% -75.54% +140.84% +83.55% -23.41% +22.54% -35.56% +32.56% -0.23% -90.43% +546.54% +37.29% +22.84% +130.53% -68.57% +106.55% -8.03% +65.19% -45.89% +45.75% +30.40% -8900.00% -100.53% +697.19% -80.72% -55.17% n/a
Sales and Marketing Revenue 20.70M 25.40M 23.20M 24.10M 20.70M 20.10M 16.90M 23.00M 17.20M 16.10M 14.50M 16.40M 17.20M 17.10M 13.70M 16.80M 12.40M 12.70M 13.00M 18.60M 14.80M 13.70M 13.60M -28.90M n/a 15.60M 13.30M 17.60M 15.80M 15.50M 15.40M -67.10M 20.10M 24.70M 22.30M n/a n/a n/a n/a
Sales and Marketing Revenue Growth -18.50% +9.48% -3.73% +16.43% +2.99% +18.93% -26.52% +33.72% +6.83% +11.03% -11.59% -4.65% +0.58% +24.82% -18.45% +35.48% -2.36% -2.31% -30.11% +25.68% +8.03% +0.74% -147.06% n/a -100.00% +17.29% -24.43% +11.39% +1.94% +0.65% -122.95% -433.83% -18.62% +10.76% n/a n/a n/a n/a n/a

Create Price Alert on UTHR

Your price alert will notify you when the stock price is above 364.56.

Add to Watchlist